We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

80 hedge funds and large institutions have $123M invested in Crescent Biopharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,004% more call options, than puts

Call options by funds: $2.9M | Put options by funds: $263K

0.09% less ownership

Funds ownership: 0.93% → 0.84% (-0.09%)

8% less funds holding

Funds holding: 87 → 80 (-7)

19% less capital invested

Capital invested by funds: $152M → $123M (-$29.1M)

26% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 31

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
80
Holders Change
-7
Holders Change %
-8.05%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
31
Closed
13
Calls
$2.9M
Puts
$263K
Net Calls
+$2.64M
Net Calls Change
+$2.47M

Top Buyers

1
EC
EcoR1 Capital
California
+$7.02M
2
N
Nuveen
North Carolina
+$725K
3
Bank of America
Bank of America
North Carolina
+$709K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$631K
5
CM
Caption Management
Oklahoma
+$570K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.37M
2
CCM
Camber Capital Management
Massachusetts
-$1.91M
3
Morgan Stanley
Morgan Stanley
New York
-$1.37M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.25M
5
BCM
Bridgeway Capital Management
Texas
-$691K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
51
Ameriprise
Minnesota
$74K +$11.8K +31 +15%
MAM
52
Marquette Asset Management
Minnesota
$72K – – –
Manulife (Manufacturers Life Insurance)
53
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$69K +$85.6K +224 New
AIG
54
American International Group
New York
$68K +$5.73K +15 +7%
Barclays
55
Barclays
United Kingdom
$62K -$20.3K -53 -21%
SEI Investments
56
SEI Investments
Pennsylvania
$61K – – –
Deutsche Bank
57
Deutsche Bank
Germany
$58K +$8.41K +22 +13%
ZIM
58
Zacks Investment Management
Illinois
$52K – – –
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
$51K -$104K -272 -62%
DT
60
Diversified Trust
Tennessee
$48K – – –
Ohio Public Employees Retirement System (OPERS)
61
Ohio Public Employees Retirement System (OPERS)
Ohio
$48K – – –
LP
62
LMR Partners
United Kingdom
$46K – – –
JC
63
JBF Capital
Colorado
$46K +$57.3K +150 New
AIM
64
Alambic Investment Management
California
$42K +$52.7K +138 New
ProShare Advisors
65
ProShare Advisors
Maryland
$38K +$2.29K +6 +5%
VOYA Investment Management
66
VOYA Investment Management
Georgia
$34K – – –
State Board of Administration of Florida Retirement System
67
State Board of Administration of Florida Retirement System
Florida
$31K – – –
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
$26.3K +$26K +68 +378%
Simplex Trading
69
Simplex Trading
Illinois
$23K – – –
Russell Investments Group
70
Russell Investments Group
United Kingdom
$18K -$62.3K -163 -73%
Citigroup
71
Citigroup
New York
$16K -$10.7K -28 -35%
HFM
72
Hartford Financial Management
Connecticut
$11K – – –
Legal & General Group
73
Legal & General Group
United Kingdom
$9K -$4.59K -12 -29%
AIP
74
Ameritas Investment Partners
Nebraska
$9K – – –
Bank of Montreal
75
Bank of Montreal
Ontario, Canada
$6K -$3.44K -9 -35%
1 2
3
4

CBIO Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2020, worth a combined $123M — down 19% from $152M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CBIO and 7 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 23 added.

The largest buyer was EcoR1 Capital, adding an estimated $7.02M. The largest seller was Wellington Management Group, cutting an estimated $3.37M.

  • 80 institutional investors held Crescent Biopharma (CBIO) as of Q3 2020, down from 87 in Q2 2020.
  • Funds reported $123M of Crescent Biopharma stock for Q3 2020, down 19% quarter-over-quarter.
  • 7 funds opened new Crescent Biopharma positions in Q3 2020 and 13 closed out, a net change of -6 holders.
  • The largest Crescent Biopharma buyer in Q3 2020 was EcoR1 Capital, an estimated $7.02M added.
  • The largest Crescent Biopharma seller in Q3 2020 was Wellington Management Group, an estimated $3.37M sold.

Based on aggregated 13F filings for Q3 2020.